148 related articles for article (PubMed ID: 33554797)
1. [The Impact of Induction Treatment Response on the Prognosis of Pediatric Core Binding Factor-Acute Myeloid Leukemia Patients].
Zeng HM; Hu GH; Lu AD; Jia YP; Zuo YX; Wu J; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):56-61. PubMed ID: 33554797
[TBL] [Abstract][Full Text] [Related]
2. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
3. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
Wu J; Lu AD; Zhang LP; Zuo YX; Jia YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):52-57. PubMed ID: 30704229
[No Abstract] [Full Text] [Related]
4. Attempts to optimize postinduction treatment in childhood acute myeloid leukemia without core-binding factors: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG).
Hasegawa D; Tawa A; Tomizawa D; Watanabe T; Saito AM; Kudo K; Taga T; Iwamoto S; Shimada A; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Miyachi H; Horibe K; Nakahata T; Adachi S
Pediatr Blood Cancer; 2020 Dec; 67(12):e28692. PubMed ID: 32886449
[TBL] [Abstract][Full Text] [Related]
5. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
[TBL] [Abstract][Full Text] [Related]
6. Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.
Fu W; Hu Y; Lu G; Xu L; Gao L; Chen J; Chen L; Tang G; Ni X; Yang J
Ann Hematol; 2023 Feb; 102(2):329-335. PubMed ID: 36633637
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
Lei M; Liu L; Wang Z; Wu D
Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and prognostic factors in children with non-core binding factor acute myeloid leukemia].
Chen XY; Liu C; Wu WQ; Zhang AL; Liu LP; Lan Y; Cai YL; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 May; 22(5):466-472. PubMed ID: 32434642
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Analysis of Pediatric Acute Myeloid Leukemia with CCLG-AML 2015 Regimen].
Wang P; Xiong H; Li JX; Wang Z; Yang L; Tao F; Chen Z; DU Y; Zhang AP; Luo LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):373-380. PubMed ID: 35395966
[TBL] [Abstract][Full Text] [Related]
11. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
12. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
[TBL] [Abstract][Full Text] [Related]
13. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
15. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics and Prognosis of 24 Cases of Primary Acute Myeloid Leukemia with Trisomy 8].
Wang JH; Yao B; Guo M; Qiao JH; Sun QY; Hu KX; Li BX; Yu CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):655-61. PubMed ID: 27342486
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
19. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]